An interventional study of Survey and Rectal Expulsion Device use in Constipation, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by University of Michigan · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 346 studies in Constipation with a site in United States — 28 open to participants now, 39 under way, 5 of them phase 3. Constipation · United States.
Among the 346 studies in Constipation with a site in United States, this one is the 208th largest by enrollment of the 308 interventional ones that give a count, is one of 13 that started in 2025, is one of 96 with no phase, and was the 326th registered.
1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.
Browse Constipation studies →28 of the 346 studies in Constipation with a site in United States are open now. Recruiting first, the newest first:
Radicle Science · Sites in United States
Ages 21–105 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 5 more countries
Ages 18–75
Peach Perfect · Sites in United States
Ages 18–60
Ardelyx · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
346 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 88 · Phase 3 73 · Phase 4 49
First in 1996; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 75 across 889 interventional studies indexed under Constipation.
Median enrollment 73 across the 308 interventional studies, 101 across the 32 observational. Of the 281 that completed or were terminated, 136 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 346 have an industry lead sponsor. The 10 most frequent:
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
University of Michigan has 7 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
20 of the studies in Constipation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT05519683Phase 3University of MichiganHome Transcutaneous Electrical Acustimulation (TEA) | 2027-03 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
| NCT05465629ViomeViome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 346 studies in Constipation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is studying how the availability of a Food and Drug Administration (FDA)-cleared point-of-care, bedside device bedside device called Rectal Expulsion Device (RED) can be used to evaluate constipation in the participants' routine office visit with the participants' care provider. In this research, participants will be asked to complete a survey prior to the gastroenterology office consultation. Health-related information will be collected for this research study. There are no additional study visits for this research study.
This registration is (Implementation Phase) for the registered study "Guideline to Implementation: A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation" (Observational Phase) NCT06352827.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Participant has Chronic constipation as a main symptom
Exclusion Criteria Participants:
Participants will complete surveys and may or may not have the Rectal Expulsion Device (FDA 510k approved) used during clinic visit.
Behavioral: Survey · Behavioral: Rectal Expulsion Device use
All participants will complete a baseline survey and have medical information collected.
During the participant's clinic visit for constipation, the Rectal Expulsion Device will be available for the gastroenterology care provider to use if the decision is made to use this during the clinic visit. In addition, the care provider will have access to the RED brochure and the Michigan Chart (MICHART) Our Practice Advisory (OPA) - a decision support tool in MiChart to support care navigation using RED.
Percentage of encounters in which anorectal physiology testing is ordered or performed at the baseline routine-care gastroenterology office appointment
Fidelity to ordering pelvic floor diagnostics
Time frame: Day 1 (Baseline = initial appointment after consent)]
Percentage of encounters in which pelvic floor physical therapy is ordered at the baseline routine-care gastroenterology office appointment
Fidelity to ordering pelvic floor treatment
Time frame: Day 1 (Baseline = initial appointment after consent)]
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2025 to primary completion in Sep 2026, 12 months.
Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 12 months is below that.
Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Feb 2027 → Sep 2026 and completion Feb 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.